GV is among the investors in the pharmaceutical manufacturing technology startup, which recently secured $750m in series B funding.
Resilience, a US-based developer of medical manufacturing technology, emerged from stealth yesterday with over $800m in funding from investors including GV, a subsidiary of internet and technology group Alphabet.
GV participated in a recently closed $750m series B round co-led by Arch Venture Partners and 8VC and also backed by fellow venture capital firm New Enterprise Associates and unnamed pharmaceutical companies, public mutual funds, foundations, family offices and pension funds.
Founded earlier this year and also known as National Resilience,…
